vs
奎斯特诊断（IMDX）与Lantheus Holdings, Inc.（LNTH）财务数据对比。点击上方公司名可切换其他公司
Lantheus Holdings, Inc.的季度营收约是奎斯特诊断的357.1倍（$406.8M vs $1.1M）。Lantheus Holdings, Inc.净利率更高（13.3% vs -2015.4%，领先2028.7%）。Lantheus Holdings, Inc.同比增速更快（4.0% vs -23.4%）。Lantheus Holdings, Inc.自由现金流更多（$81.4M vs $-7.0M）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs 4.9%）
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
IMDX vs LNTH — 直观对比
营收规模更大
LNTH
是对方的357.1倍
$1.1M
营收增速更快
LNTH
高出27.4%
-23.4%
净利率更高
LNTH
高出2028.7%
-2015.4%
自由现金流更多
LNTH
多$88.4M
$-7.0M
两年增速更快
IMDX
近两年复合增速
4.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $406.8M |
| 净利润 | $-23.0M | $54.1M |
| 毛利率 | 42.5% | 59.2% |
| 营业利润率 | -2057.5% | 19.0% |
| 净利率 | -2015.4% | 13.3% |
| 营收同比 | -23.4% | 4.0% |
| 净利润同比 | 31.5% | 558.8% |
| 每股收益（稀释后） | $-0.75 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMDXLNTH
| Q4 25 | $1.1M | $406.8M | ||
| Q3 25 | $260.0K | $384.0M | ||
| Q2 25 | $518.0K | $378.0M | ||
| Q1 25 | $2.1M | $372.8M | ||
| Q4 24 | $1.5M | $391.1M | ||
| Q3 24 | $115.0K | $378.7M | ||
| Q2 24 | $104.0K | $394.1M | ||
| Q1 24 | $176.0K | $370.0M |
净利润IMDXLNTH
| Q4 25 | $-23.0M | $54.1M | ||
| Q3 25 | $-10.9M | $27.8M | ||
| Q2 25 | $-9.7M | $78.8M | ||
| Q1 25 | $-6.7M | $72.9M | ||
| Q4 24 | $-33.5M | $-11.8M | ||
| Q3 24 | $-13.5M | $131.1M | ||
| Q2 24 | $-4.5M | $62.1M | ||
| Q1 24 | $-9.1M | $131.1M |
毛利率IMDXLNTH
| Q4 25 | 42.5% | 59.2% | ||
| Q3 25 | 53.5% | 57.9% | ||
| Q2 25 | 67.6% | 63.8% | ||
| Q1 25 | 62.0% | 63.8% | ||
| Q4 24 | 40.0% | 63.5% | ||
| Q3 24 | 43.5% | 63.9% | ||
| Q2 24 | 48.1% | 64.9% | ||
| Q1 24 | 25.6% | 65.4% |
营业利润率IMDXLNTH
| Q4 25 | -2057.5% | 19.0% | ||
| Q3 25 | -4249.2% | 11.4% | ||
| Q2 25 | -1900.0% | 23.3% | ||
| Q1 25 | -318.0% | 27.4% | ||
| Q4 24 | -2262.9% | 29.1% | ||
| Q3 24 | -11752.2% | 35.3% | ||
| Q2 24 | -4453.8% | 26.1% | ||
| Q1 24 | -5265.3% | 28.8% |
净利率IMDXLNTH
| Q4 25 | -2015.4% | 13.3% | ||
| Q3 25 | -4174.6% | 7.2% | ||
| Q2 25 | -1880.7% | 20.8% | ||
| Q1 25 | -312.0% | 19.6% | ||
| Q4 24 | -2255.1% | -3.0% | ||
| Q3 24 | -11733.0% | 34.6% | ||
| Q2 24 | -4355.8% | 15.8% | ||
| Q1 24 | -5186.9% | 35.4% |
每股收益（稀释后）IMDXLNTH
| Q4 25 | $-0.75 | $0.86 | ||
| Q3 25 | $-0.34 | $0.41 | ||
| Q2 25 | $-0.30 | $1.12 | ||
| Q1 25 | $-0.26 | $1.02 | ||
| Q4 24 | $-2.19 | $-0.18 | ||
| Q3 24 | $-0.98 | $1.79 | ||
| Q2 24 | $-0.36 | $0.88 | ||
| Q1 24 | $-1.13 | $1.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | $359.1M |
| 总债务越低越好 | — | $568.7M |
| 股东权益账面价值 | $-31.5M | $1.1B |
| 总资产 | $25.8M | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资IMDXLNTH
| Q4 25 | $11.6M | $359.1M | ||
| Q3 25 | $18.7M | $382.0M | ||
| Q2 25 | $24.3M | $695.6M | ||
| Q1 25 | $31.0M | $938.5M | ||
| Q4 24 | $8.6M | $912.8M | ||
| Q3 24 | $3.4M | $866.4M | ||
| Q2 24 | $9.3M | $757.0M | ||
| Q1 24 | $5.6M | $718.3M |
总债务IMDXLNTH
| Q4 25 | — | $568.7M | ||
| Q3 25 | — | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | — | $566.1M | ||
| Q4 24 | — | $565.3M | ||
| Q3 24 | — | $613.0K | ||
| Q2 24 | — | $563.2M | ||
| Q1 24 | — | $562.5M |
股东权益IMDXLNTH
| Q4 25 | $-31.5M | $1.1B | ||
| Q3 25 | $-9.2M | $1.1B | ||
| Q2 25 | $1.1M | $1.2B | ||
| Q1 25 | $10.2M | $1.2B | ||
| Q4 24 | $-12.3M | $1.1B | ||
| Q3 24 | $9.7M | $1.2B | ||
| Q2 24 | $22.7M | $1.0B | ||
| Q1 24 | $11.6M | $945.5M |
总资产IMDXLNTH
| Q4 25 | $25.8M | $2.2B | ||
| Q3 25 | $43.9M | $2.3B | ||
| Q2 25 | $50.5M | $2.1B | ||
| Q1 25 | $60.4M | $2.1B | ||
| Q4 24 | $35.1M | $2.0B | ||
| Q3 24 | $70.2M | $2.0B | ||
| Q2 24 | $74.7M | $1.9B | ||
| Q1 24 | $71.0M | $1.8B |
负债/权益比IMDXLNTH
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.5M | $90.2M |
| 自由现金流经营现金流 - 资本支出 | $-7.0M | $81.4M |
| 自由现金流率自由现金流/营收 | -616.7% | 20.0% |
| 资本支出强度资本支出/营收 | 129.9% | 2.2% |
| 现金转化率经营现金流/净利润 | — | 1.67× |
| 过去12个月自由现金流最近4个季度 | $-25.4M | $354.1M |
8季度趋势，按日历期对齐
经营现金流IMDXLNTH
| Q4 25 | $-5.5M | $90.2M | ||
| Q3 25 | $-4.5M | $105.3M | ||
| Q2 25 | $-6.3M | $87.1M | ||
| Q1 25 | $-5.9M | $107.6M | ||
| Q4 24 | $-5.4M | $157.7M | ||
| Q3 24 | $-5.5M | $175.1M | ||
| Q2 24 | $-6.0M | $84.7M | ||
| Q1 24 | $-3.8M | $127.2M |
自由现金流IMDXLNTH
| Q4 25 | $-7.0M | $81.4M | ||
| Q3 25 | $-5.6M | $94.7M | ||
| Q2 25 | $-6.6M | $79.1M | ||
| Q1 25 | $-6.2M | $98.8M | ||
| Q4 24 | $-5.6M | $141.4M | ||
| Q3 24 | $-5.6M | $159.3M | ||
| Q2 24 | $-6.2M | $73.5M | ||
| Q1 24 | $-3.9M | $119.0M |
自由现金流率IMDXLNTH
| Q4 25 | -616.7% | 20.0% | ||
| Q3 25 | -2135.4% | 24.7% | ||
| Q2 25 | -1279.5% | 20.9% | ||
| Q1 25 | -288.4% | 26.5% | ||
| Q4 24 | -374.5% | 36.1% | ||
| Q3 24 | -4884.3% | 42.0% | ||
| Q2 24 | -5931.7% | 18.7% | ||
| Q1 24 | -2189.8% | 32.2% |
资本支出强度IMDXLNTH
| Q4 25 | 129.9% | 2.2% | ||
| Q3 25 | 403.8% | 2.8% | ||
| Q2 25 | 67.4% | 2.1% | ||
| Q1 25 | 14.4% | 2.3% | ||
| Q4 24 | 14.4% | 4.2% | ||
| Q3 24 | 75.7% | 4.2% | ||
| Q2 24 | 183.7% | 2.8% | ||
| Q1 24 | 13.6% | 2.2% |
现金转化率IMDXLNTH
| Q4 25 | — | 1.67× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 1.11× | ||
| Q1 25 | — | 1.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMDX
暂无分部数据
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
